Funding for this research was provided by:
National Institutes of Health (U54CA209978)
Received: 14 January 2019
Accepted: 19 August 2019
First Online: 5 September 2019
Ethics approval and consent to participate
: This study was approved by City of Hope Institutional Review Board, 09139, titled “A Retrospective Study of Triple Negative Breast Cancer Exploring Treatment Resistant Mechanism and Correlation to Survival in All Accessible Tissues.” Written informed consent was obtained from all patients who participated in the study.
: Not applicable.
: YY has contracted clinical trials and research projects sponsored by Merck, Eisai, Novartis, Genentech, Puma and Pfizer. YY is a consultant for Puma; and a member of the Speakers Bureau for Eisai. The other authors declare that they have no competing interests.